Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Executive Summary
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products
You may also be interested in...
Strange Bedfellows: Amgen, J&J Work Together In Advance Of EPO Meeting
Amgen is working with Johnson & Johnson to ensure that a consistent message regarding the safety profile of erythropoiesis-stimulating agents is presented to FDA's Oncologic Drugs Advisory Committee
Aranesp Anemia Of Cancer Study Results Show Increased Mortality Risk
Amgen will continue to evaluate patients in its completed Phase III study of Aranesp in anemia of cancer after determining that use of darbepoetin alfa was associated with higher mortality risk
Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers
Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment